Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Application
1.1.3. Route of administration
1.1.4. Distribution channel
1.1.5. Regional scope
1.1.6. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Application outlook
2.2.3. Route of administration outlook
2.2.4. Distribution channel outlook
2.2.5. Regional outlook
2.3. Competitive Insights
Chapter 3. Opioids Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Opioids Market Analysis Tools
3.4.1. Industry Analysis – Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Opioids: Product Estimates & Trend Analysis
4.1. Opioids Market: Key Takeaways
4.2. Opioids Market: Movement & Market Share Analysis, 2022 & 2030
4.3. IR/Short Acting Opioids
4.3.1. IR/ Short Acting Opioids market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. ER/Long Acting Opioids
4.4.1. ER/ Long Acting Opioids market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Opioids: Application Estimates & Trend Analysis
5.1. Opioids Market: Key Takeaways
5.2. Opioids Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Pain Relief
5.3.1. Pain relief market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Anesthesia
5.4.1. Anesthesia market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Cough Suppression
5.5.1. Cough suppression market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Diarrhea Suppression
5.6.1. Diarrhea suppression market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. De-addiction
5.7.1. De-addiction market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Opioids: Route of Administration Estimates & Trend Analysis
6.1. Opioids Market: Key Takeaways
6.2. Opioids Market: Movement & Market Share Analysis, 2022 & 2030
6.3. Oral
6.3.1. Oral market estimates and forecasts, 2018 to 2030 (USD Million)
6.4. Injectable
6.4.1. Injectable market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Others
6.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Opioids: Distribution Channel Estimates & Trend Analysis
7.1. Opioids Market: Key Takeaways
7.2. Opioids Market: Movement & Market Share Analysis, 2022 & 2030
7.3. Hospital Pharmacy
7.3.1. Hospital pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
7.4. Retail Pharmacy
7.4.1. Retail Pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
7.5. Others
7.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. Opioids Market: Regional Estimates & Trend Analysis
8.1. Regional Outlook
8.2. Opioids Market by Region: Key Takeaways
8.3. North America
8.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.3.2. U.S.
8.3.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.3.3. Canada
8.3.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.4. Europe
8.4.1. UK
8.4.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.4.2. Germany
8.4.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.4.3. France
8.4.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.4.4. Italy
8.4.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.4.5. Spain
8.4.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.4.6. Sweden
8.4.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.4.7. Norway
8.4.7.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.4.8. Denmark
8.4.8.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.5.2. China
8.5.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.5.3. India
8.5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.5.4. Australia
8.5.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.5.5. Thailand
8.5.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.5.6. South Korea
8.5.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.6.2. Mexico
8.6.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.6.3. Argentina
8.6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.7. MEA
8.7.1. Saudi Arabia
8.7.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.7.2. South Africa
8.7.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.7.3. UAE
8.7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.7.4. Kuwait
8.7.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Market Participant Categorization
9.2.1. Purdue Pharma L.P.
9.2.1.1. Company overview
9.2.1.2. Financial performance
9.2.1.3. Product benchmarking
9.2.1.4. Strategic initiatives
9.2.2. Johnson & Johnson Services, Inc.
9.2.2.1. Company overview
9.2.2.2. Financial performance
9.2.2.3. Product benchmarking
9.2.2.4. Strategic initiatives
9.2.3. Hikma Pharmaceuticals PLC
9.2.3.1. Company overview
9.2.3.2. Financial performance
9.2.3.3. Product benchmarking
9.2.3.4. Strategic initiatives
9.2.4. Pfizer Inc.
9.2.4.1. Company overview
9.2.4.2. Financial performance
9.2.4.3. Product benchmarking
9.2.4.4. Strategic initiatives
9.2.5. AbbVie Inc.
9.2.5.1. Company overview
9.2.5.2. Financial performance
9.2.5.3. Product benchmarking
9.2.5.4. Strategic initiatives
9.2.6. Sanofi
9.2.6.1. Company overview
9.2.6.2. Financial performance
9.2.6.3. Product benchmarking
9.2.6.4. Strategic initiatives
9.2.7. Sun Pharmaceutical Industries Ltd
9.2.7.1. Company overview
9.2.7.2. Financial performance
9.2.7.3. Product benchmarking
9.2.7.4. Strategic initiatives
9.2.8. Grünenthal
9.2.8.1. Company overview
9.2.8.2. Financial performance
9.2.8.3. Product benchmarking
9.2.8.4. Strategic initiatives
9.2.9. Merck & Co., Inc.
9.2.9.1. Company overview
9.2.9.2. Financial performance
9.2.9.3. Product benchmarking
9.2.9.4. Strategic initiatives
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/